| 0 (0%) | 09-27 11:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.7 | 1-year : | 35.88 |
| Resists | First : | 29.71 | Second : | 30.72 |
| Pivot price | 29.06 |
|||
| Supports | First : | 28.09 | Second : | 23.37 |
| MAs | MA(5) : | 29.21 | MA(20) : | 29.12  |
| MA(100) : | 30.65 |
MA(250) : | 28.9 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 87.5 |
D(3) : | 82 |
| RSI | RSI(14): 44 | |||
| 52-week | High : | 32.5 | Low : | 24.77 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ UTRN ] has closed below upper band by 37.4%. Bollinger Bands are 23.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.25 - 29.39 | 29.39 - 29.51 |
| Low: | 28.87 - 29.04 | 29.04 - 29.18 |
| Close: | 28.97 - 29.23 | 29.23 - 29.45 |
Mon, 16 Jun 2025
Middle Eastern Penny Stocks To Watch In June 2025 - simplywall.st
Wed, 07 May 2025
Modernising stamp duty on shares - Tax Journal
Tue, 22 Apr 2025
The Universal Trial Number (UTN) - World Health Organization (WHO)
Wed, 12 Feb 2025
Transcriptional adaptation upregulates utrophin in Duchenne muscular dystrophy - Nature
Tue, 08 Oct 2024
FDA Grants Orphan Drug Designation to Becker and Duchenne Agent RAG-18 - NeurologyLive
Tue, 30 Jul 2024
saRNA Therapy Gets Rare Pediatric Disease Designation for DMD - CGTLive®
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|